Desmopressin applicability in the management of congenital coagulopathies: a literature review (Atena Editora)

Abstract

Blood clotting is a complex process that, when disturbed, can result in coagulopathies, making individuals more prone to excessive bleeding. In this scenario, desmopressin has emerged as a valuable therapeutic tool. This article reviews the applicability of desmopressin in the management of coagulopathies, focusing on the main conditions in which this medication has demonstrated efficacy. Von Willebrand disease (vWD), an inherited coagulopathy, is characterized by deficiency or dysfunction of von Willebrand factor (vWF). Clinical studies have shown that desmopressin is capable of temporarily increasing vWF levels in plasma, resulting in significant improvements in hemostasis. This makes it an effective treatment option for the prophylaxis and treatment of bleeding in patients with VWD. Furthermore, desmopressin also shows promise in the treatment of some thrombocytopathies, such as Bernard-Soulier syndrome and thrombocytopathy associated with von Willebrand disease. These conditions are characterized by abnormalities in blood platelets. Studies have shown that desmopressin can stimulate platelet adhesion and improve platelet function in certain cases of thrombocytopathies, offering an additional therapeutic approach. However, it is critical to recognize that the effectiveness of desmopressin may vary between patients and that its use requires careful monitoring. Furthermore, accurate identification of the type of coagulopathy and the individual response to desmopressin are critical to determining the most appropriate treatment. In conclusion, desmopressin represents an important therapeutic option in the treatment arsenal of coagulopathies, offering hope and relief to those suffering from these complex conditions.